Kunena :: Тема: Posted by vindasreiho1987 on 30.11.2016 10:42:31: erlotinib plattenepithelkarzinom (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by vindasreiho1987 on 30.11.2016 10:42:31: erlotinib plattenepithelkarzinom

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by vindasreiho1987 on 30.11.2016 10:42:31: erlotinib plattenepithelkarzinom

Страница:
1
2

ТЕМА: Posted by vindasreiho1987 on 30.11.2016 10:42:31: erlotinib plattenepithelkarzinom

Posted by vindasreiho1987 on 30.11.2016 10:42:31: erlotinib plattenepithelkarzinom 7 года 5 мес. назад #941

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
"tarceva cloridrato de erlotinibe 150mg"
Before doing EGFR and KRAS tests on a routine basis and taking the results into account when making a decision about who should be treated with gefitinib or erlotinib, larger studies need to be done to see whether the results reported here hold up.
Analyses of toxicity and molecular and genetic profiles failed to identify subsets of GBM patients who might derive a survival benefit from erlotinib concurrent with TMZ and RT. There was a trend ( P = .103) to better survival for EGFR -amplified patients; however, the significance of this result is questionable given the number of tested variables and lack of Bonferroni corrections. Therefore, although the subsets of patients with molecular and genetic profiles were small, this trial does not suggest that there would be a benefit for the use of erlotinib in combination with RT and TMZ in a selected population such as those with EGFR amplification or mutation.
42. Pao W, Miller VA, Politi KA. et al . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain . PLoS Med. 2005; 2 (3):e73
advocate-ogorodnikov.ru/index.php/kunena...cer-survival-tarceva
The European Commission approved bevacizumab (Avastin) in combination with erlotinib (Tarceva) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent EGFR -mutant non–small cell lung cancer (NSCLC).
The treatment effect was not significantly different between elderly and young patients (interaction, P = .31). For elderly patients, median survival time was 7.6 months for patients receiving erlotinib compared with 5.0 months for patients receiving placebo (HR = 0.92; 95% CI, 0.64 to 1.34; P = .67), and for young patients, the median survival times were 6.4 months compared with 4.7 months (HR = 0.73; 95% CI, 0.61 to 0.89; P = .0014; Figs 1C and 1D ).
megaservis-pk.ru/index.php/kunena/dobro-...arceva-stops-working
Patients will receive gemcitabine either alone or with erlotinib. Patients will be randomly assigned to one treatment group or the other. Erlotinib is a pill that may help treat cancers by blocking a gene that is important in cancer growth. It is approved for treating advanced pancreatic cancer, but its use to prevent pancreatic cancer from returning after surgery is considered investigational.
Participants with tumors found to harbor EGFR mutations or rearrangements in the ALK gene will be referred to the ALCHEMIST treatment trials evaluating specific drugs targeted against these genetic alterations, erlotinib and crizotinib, respectively. Participants enrolled on these treatment trials will be randomized to receive either the targeted agent or placebo.
For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.
www.alym.38kir.ru/index.php/forum/dobro-...2-tarceva-drug-label
Le caratteristiche demografiche erano ben bilanciate tra i due gruppi di trattamento. Circa due terzi dei pazienti erano maschi, un terzo circa aveva un performance status (PS) ECOG all’ingresso di 2 e il 9 % un PS ECOG all’ingresso di 3. Il 93 % e il 92 % di tutti i pazienti, rispettivamente del gruppo Tarceva e del gruppo placebo, erano stati trattati in precedenza con un regime a base di platino e il 36 % e il 37 % di tutti i pazienti, rispettivamente, erano stati trattati in precedenza con taxani.
Cc-Pharma GmbH Filmtabletten | 30 ST PZN: 189078 z. Zt. keine Angebote Tarceva 25mg Filmtabl. 30 ST
www.pneumatica.com.ua/component/kunena/2...on-egfr?lang=ru#6002
I. To compare the progression-free survival (PFS) associated with patients treated with erlotinib (erlotinib hydrochloride) versus (vs) erlotinib plus cabozantinib (cabozantinib-s-malate).
11. Lazzari C, Novello S, Barni S, et al: Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). J Clin Oncol 31:LBA8005, 2013.
Marina Chiara Garassino, Olga Martelli, Massimo Broggini, Gabriella Farina, Silvio Veronese, Eliana Rulli, Filippo Bianchi, Anna Bettini, Flavia Longo, Luca Moscetti, Maurizio Tomirotti, Mirko Marabese, Monica Ganzinelli, Calogero Lauricella, Roberto Labianca, Irene Floriani, Giuseppe Giaccone, Valter Torri, Alberto Scanni, Silvia Marsoni. (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. The Lancet Oncology 14 . 981-988. CrossRef
COS-7 cells transiently transfected with EGFR plasmid constructs (wild-type, L858R, E884K, and L858R + E884K [created by site-directed mutagenesis as previously described 16 ]) were treated with increasing concentrations of either ( A ) erlotinib or ( B ) gefitinib, in the presence of EGF (100 ng/ml, 30 min). Whole cell lysates were collected after EGF stimulation, separated on 7.5% SDS-PAGE and electrotransferred onto nitrocellulose membrane for immunoblotting. The membrane was probed with an antibody against phospho-EGFR [pY1068] (upper panel) and -actin (lower panel) as a loading control. Equivalent receptor expression was also confirmed with an anti-EGFR immunoblot (see Supplementary Figure 1 online). Two separate immunoblotting experiments were used for quantitative analysis of the phospho-EGFR signal intensity. U, cells untreated with TKI; WT, wild-type. ( C ) Percentage (%) phospho-EGFR signal level compared with the untreated control (100%) plotted for EGFR L858R -COS-7and EGFR L858R + E884K -COS-7 cell lines treated with either of the two EGFR TKIs at 0.1 M. The EGF-stimulated phospho-EGFR activation of L858R mutation is modulated by the E884K mutation differentially with erlotinib (resistant) and gefitinib (sensitizing) as shown here at the in vitro concentration of 0.1 M. The percentage phospho-EGFR signal level (%) relative to untreated control (100%) was shown for both the L858R and L858R + E884K mutations to illustrate how E884K differentially modulates the sensitizing effect of L858R on the receptor towards the two different inhibitors. ( D ) Multiple sequence alignment performed by the CLUSTAL W alignment program for exon 22 of ErbB1, 2, and 3 of the ErbB receptor family. The black arrow shows the conserved nucleotide G that was mutated in our patient's tumor EGFR gene and the arrow outline and bold text shows the conserved amino acid residue glutamic acid, E884. The methods are further described in the Supplementary methods section; please go to the article online for details. * Conserved nucleotides among the three sequences; IB, immunoblot.
This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma. The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response.
medtomorrow.dp.ua/forum/post
Like other medicines, Erlotinib can cause some side effects. If they do occur, the side effects of Erlotinib are most likely to be minor and temporary. However, some may be serious and may require the individual to inform the doctor or visit the nearest hospital immediately.
In terms of how we use them, it depends on the provider, depending on what you’re used to using and what you’ve potentially, read about in terms of potential advantages like side effects. I would say that it’s very common in this country to use erlotinib. That’s been the approved agent for many years now, so many oncologists are familiar with erlotinib. We primarily use erlotinib for patients who have newly diagnosed metastatic EGFR-mutant lung cancer.
Switching to Afatinib After Progression on Erlotinib or Gefitinib
Erlotinib, pemetrexed and perhaps docetaxel (which demonstrated PFS but not overall survival benefit) are potential current options for maintenance chemotherapy in this setting. However, as the use of pemetrexed is currently migrating into the frontline setting for patients with nonsquamous NSCLC, one outstanding question is whether continuing a relatively tolerable first-line agent such as pemetrexed as maintenance is equivalent to switching to a new second-line drug. The IFCT-GFPC 0502 study investigated this question using gemcitabine and suggests that there may at least be a PFS benefit to continuing a tolerable first-line drug in the maintenance setting.
Q. Does anyone know anything about the drug Tarceva (from Genentech)?
biz.fksavoya.ru/index.php/forum
Selleck Chemicals - S1023-10G - ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE (Each (10g))
liveinmersin.com/index.php/kunena/razdel...37-erlotinib-erlonat
Taken as an oral, once-daily therapy, Tarceva is the only EGFR-inhibitor to have demonstrated a survival benefit in lung cancer. Currently most lung cancer patients are treated with chemotherapy which can be very debilitating due to its toxic nature. Tarceva works differently to chemotherapy by specifically targeting tumour cells, so avoiding the unpleasant side-effects of chemotherapy.
Erlotinib has promising potential to improve treatment for cervical cancer
The use of erlotinib after gefitinib failure in patients with non-small cell lung cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of erlotinib after failure of gefitinib.